InvestSMART

Factor Therapeutics Limited (ASX: FTT) - Announcements

- Current share price for FTT : $0.005

ASX company news and announcements for Factor Therapeutics Limited (FTT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Factor Therapeutics Limited (FTT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Factor Therapeutics Limited (FTT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Factor Therapeutics Limited (FTT)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
- Notice of despatch of Rights Issue documents 22 Mar 2018 4:10PM $0.042 $0.005 fallen by 88.10%
- Appendix 4G for transitional period to 31 December 2017 22 Mar 2018 1:19PM $0.042 $0.005 fallen by 88.10%
- Corporate Governance Statement to 31 December 2017 22 Mar 2018 1:18PM $0.042 $0.005 fallen by 88.10%
- Annual Report for transitional period to 31 December 2017 22 Mar 2018 1:18PM $0.042 $0.005 fallen by 88.10%
- Appendix 3B Rights Issue shares - correction to issue date 14 Mar 2018 12:43PM $0.043 $0.005 fallen by 88.37%
- Rights Issue - Letter to option holders 14 Mar 2018 9:01AM $0.047 $0.005 fallen by 89.36%
- Rights Issue - Letter to ineligible holders 14 Mar 2018 9:00AM $0.047 $0.005 fallen by 89.36%
- Rights Issue - Letter to eligible holders 14 Mar 2018 9:00AM $0.047 $0.005 fallen by 89.36%
- Appendix 3B - Rights Issue Entitlement Offer 14 Mar 2018 9:00AM $0.047 $0.005 fallen by 89.36%
- Rights Issue Entitlement Offer Information Booklet 14 Mar 2018 9:00AM $0.047 $0.005 fallen by 89.36%
- Factor announces fully underwritten entitlement offer 14 Mar 2018 8:59AM $0.047 $0.005 fallen by 89.36%
- Investor Presentation 14 Mar 2018 8:59AM $0.047 $0.005 fallen by 89.36%
- Rights Issue Entitlement Offer - Cleansing Notice 14 Mar 2018 8:57AM $0.047 $0.005 fallen by 89.36%
- Trading Halt 12 Mar 2018 9:08AM $0.047 $0.005 fallen by 89.36%
- Clinical Trial Update 5 Mar 2018 8:21AM $0.042 $0.005 fallen by 88.10%
- Appendix 4E Preliminary Final Report 22 Feb 2018 12:45PM $0.039 $0.005 fallen by 87.18%
- One-hundredth patient recruited in VF001002 clinical trial 8 Feb 2018 8:28AM $0.038 $0.005 fallen by 86.84%
- Appendix 4C - December 2017 Quarter 25 Jan 2018 12:58PM $0.043 $0.005 fallen by 88.37%
- Change in financial year end 23 Jan 2018 12:31PM $0.046 $0.005 fallen by 89.13%
- Clinical Trial Update 18 Jan 2018 8:29AM $0.047 $0.005 fallen by 89.36%
- Shareholder Update 15 Jan 2018 8:26AM $0.050 $0.005 fallen by 90%
- Change in substantial holding 10 Jan 2018 6:12PM $0.047 $0.005 fallen by 89.36%
- Link Market Services - Change of Brisbane Address 18 Dec 2017 3:12PM $0.048 $0.005 fallen by 89.58%
- Factor receives $3.1M R&D tax rebate 5 Dec 2017 8:23AM $0.050 $0.005 fallen by 90%
- 50% recruitment reached in VF00102 Clinical Trial 29 Nov 2017 8:40AM $0.047 $0.005 fallen by 89.36%

151 - 175 of 260 results

Page 7 of 11

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.